NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen
Biosensors and Bioelectronics · 2023-03 · 224 · 115063
DOI: 10.1016/j.bios.2023.115063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biosensors and Bioelectronics, 2023-03. Verfasst von Zhaorui Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China; State Key La…. Hauptthemen laut MEDLINE: Biosensing Techniques, Nanoparticles. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Fluorescent lateral flow immunoassay (LFA) is one of the most common analytical platforms for point-of-care testing (POCT), which is capable of facile and early screening of biomarkers. Notably, fluorescent probes play a decisive role in analytical performances of LFA. Herein, we report a novel LFA based on the rare earth doped nanoparticles (RENPs) emitting in the second near-infrared (NIR-II) window for the detection of biomarkers, such as carcinoembryonic antigen (CEA). Benefiting from the dual fluorescent emission at NIR-II window, strong fluorescent penetration, low autofluorescence and excellent photostability of RENPs, this proposed NIR-II LFA displays a good linear relationship ranging from 1 to 320 ng mL-1. The detection limit is as low as 0.37 ng mL-1, which is of 13.5 times lower than the clinical cutoff value. Overall, NIR-II LFA biosensing platform based RENPs not only exhibits high sensitivity, accuracy and specificity, but also have characteristics of rapidity, simplicity and low cost. It holds high potential for early diagnosis of tumor biomarkers in POCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China; State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institut…
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China; Institute of Molecular Medicine Joint Laboratory for Molecular Medicine Northeaste…
- State Key Laboratory of Drug Research, Molecular Imaging Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, Shandong, 264117, China.
Zitieren
APA
Song, Z., Suo, Y., Duan, S., Zhang, S., Liu, L., Chen, B., & Cheng, Z. (2023). NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen. Biosensors and Bioelectronics, 224, 115063. https://doi.org/10.1016/j.bios.2023.115063
Vancouver
Song Z, Suo Y, Duan S, Zhang S, Liu L, Chen B, et al. NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen. Biosensors and Bioelectronics. 2023;224:115063. doi:10.1016/j.bios.2023.115063
BibTeX
@article{Song2023,
author = {Song, Zhaorui and Suo, Yongkuan and Duan, Shuang and Zhang, Shanshan and Liu, Lifu and Chen, Botong and Cheng, Zhen},
title = {NIR-II fluorescent nanoprobe-labeled lateral flow biosensing platform: A high-performance point-of-care testing for carcinoembryonic antigen},
journal = {Biosensors and Bioelectronics},
year = {2023},
volume = {224},
pages = {115063},
doi = {10.1016/j.bios.2023.115063}
}
EUVIMED